arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Ceribell, Inc.

CBLL
$18.79 ▲ +0.56 (+3.07%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
14 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Ceribell, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $707.7M
Dividend Yield
Revenue Growth 29.3%
Op. Margin -78.3%
ROIC -11.6%
FCF / Share $-0.52
Trailing P/E
Price / Book 5.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$26.49M
↑ +29.3%
Net Income Profit after all expenses
$-19.74M
↓ -54.5%
Operating Margin Operating profit as % of sales
-78.3%
↓ -33.0% 4th
FCF / Share Free cash flow per share
$-0.52
↓ -60.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
21
Financial Health
21
Cash Quality
52

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters